The finding that BRAF mutations in primary melanomas is not always identified in the correspondent metastases can also partly explain the high percentage of BRAF mutations observed in our cohort of primary tumors (62% with at least two methods) compared to the literature, in which only metastatic tissue is evaluated. The gene discussed is BRAF; the disease is melanoma.